As Drug-Resistant Microbes Rise, Antibiotic Start-Ups Need Savvy Investors
This article was originally published in Start Up
Executive SummaryVCs see rich exit opportunities, especially for start-ups with multiple products in their pipelines. In this issue we profile four emerging antibiotic drug developers: Cempra Pharmaceuticals, DesignMedix, Kenta Biotech and MGB Biopharma.
You may also be interested in...
The Boston-based drug developer believes it has resolved the regulatory issues that led to the dissolution of a partnership with Novartis around the drug omadacycline.